Christopher Rudd has contributed significantly to the fields of immunology and immunotherapy by defining key signalling events needed for the activation and function of T-cells. He was the Professor of Molecular Immunology at the University of Cambridge (UK) and held professorial positions at Harvard Medical School, and Imperial College London before returning to Canada several years ago. His work established the scientific groundwork for therapeutic approaches employed in the treatment of patients suffering from immune-related clinical conditions and cancer. Christopher Rudd is globally acknowledged as a pioneer in the rapidly expanding domain of immunotherapy.